Place conditioning to apomorphine in rat models of Parkinson's disease: Differences by dose and side-effect expression

Campbell, Joannalee C.; Jeyamohan, Shiveindra; Cruz, Priscilla De La; Chen, Nita; Shin, Damian S.; Pilitsis, Julie G.

doi:10.1016/j.bbr.2014.09.002

Cited by 14 publications

(11 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, apomorphine can reduce glucose metabolism in the left frontal region and, at the same time, increase glucose metabolism in right occipital temporal region. This will positively regulate the motor function and mood of PD patients and change the motor, cognitive, and motivational state of brain regions in PD patients to improve their quality of life [52, 53]. Second, apomorphine may alter the expression of important early PD-related genes.…”

Section: Discussionmentioning

confidence: 99%

“…However, apomorphine will easily degrade under light, and it can inhibit the central nervous system, which causes persistent vomiting, shortness of breath, respiratory depression, acute circulatory failure, coma, death and eosinophilia. Bradycardia and hypotension can occur 5-10 min after treatment and can even progress to acute circulatory failure [53, 57]. …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson’s Disease: a Network Meta-Analysis

Li¹,

Cui²,

Song³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: A network meta-analysis is used to compare the efficacy of ropinirole, rasagiline, rotigotine, entacapone, apomorphine, pramipexole, sumanirole, bromocriptine, piribedil and levodopa, with placebo as a control, for non-motor symptoms in Parkinson’s disease (PD). Methods: PubMed, Embase and the Cochrane Library were searched from their establishment dates up to January 2017 for randomized controlled trials (RCTs) investigating the efficacy of the above ten drugs on the non-motor symptoms of PD. A network meta-analysis combined the evidence from direct comparisons and indirect comparisons and evaluated the pooled weighted mean difference (WMD) values and surfaces under the cumulative ranking curves (SUCRA). The network meta-analysis included 21 RCTs. Results: The analysis results indicated that, using the United Parkinson’s Disease Rating Scale (UPDRS) III, the efficacies of placebo, ropinirole, rasagiline, rotigotine, entacapone, pramipexole, sumanirole and levodopa in treating PD were lower than that of apomorphine (WMD = -10.90, 95% CI = -16.12∼-5.48; WMD = -11.85, 95% CI = -17.31∼-6.16; WMD = -11.15, 95% CI = -16.64∼-5.04; WMD = -11.70, 95% CI = -16.98∼-5.60; WMD = -11.04, 95% CI = -16.97∼-5.34; WMD = -13.27, 95% CI = -19.22∼-7.40; WMD = -10.25, 95% CI = -15.66∼-4.32; and WMD = -11.60, 95% CI = -17.89∼-5.57, respectively). Treatment with ropinirole, rasagiline, rotigotine, entacapone, pramipexole, sumanirole, bromocriptine, piribedil or levodopa, with placebo as a control, on PD exhibited no significant differences on PD symptoms when the UPDRS II was used for evaluation. Moreover, using the UPDRS III, the SUCRA values indicated that a pomorphine had the best efficacy on the non-motor symptoms of PD (99.0%). Using the UPDRS II, the SUCRA values for ropinirole, rasagiline, rotigotine, entacapone, pramipexole, sumanirole, bromocriptine, piribedil and levodopa treatments, with placebo as a control, indicated that bromocriptine showed the best efficacy on the non-motor symptoms of PD (75.6%). Conclusion: Among ropinirole, rasagiline, rotigotine, entacapone, apomorphine, pramipexole, sumanirole, bromocriptine, piribedil and levodopa, with placebo as a control, apomorphine may be the most efficacious drug for therapy in treating the non-motor symptoms of PD.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson’s Disease: a Network Meta-Analysis

Li¹,

Cui²,

Song³

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

show abstract

“…However, the rewarding properties of apomorphine and pramipexole are increased in animals with a lesion of the SN (Campbell et al 2014;Riddle et al 2012).…”

Section: Addiction To Da Replacement Therapy Medications In Parkinsonmentioning

confidence: 99%

Dopamine and addiction: what have we learned from 40 years of research

et al. 2018

View full text Add to dashboard Cite

Among the neurotransmitters involved in addiction, dopamine (DA) is clearly the best known. The critical role of DA in addiction is supported by converging evidence that has been accumulated in the last forty years. In the present review, firstly we describe the dopaminergic system in terms of connectivity, functioning and involvement in reward processes. Secondly, we describe the functional, structural, and molecular changes induced by drugs within the DA system in terms of neuronal activity, synaptic plasticity and transcriptional and molecular adaptations. Thirdly, we describe how genetic mouse models have helped characterizing the role of DA in addiction. Fourthly, we describe the involvement of the DA system in the vulnerability to addiction and the interesting case of addiction DA replacement therapy in Parkinson's disease. Finally, we describe how the DA system has been targeted to treat patients suffering from addiction and the result obtained in clinical settings and we discuss how these different lines of evidence have been instrumental in shaping our understanding of the physiopathology of drug addiction.

show abstract

“…It has been well established that the ability of a drug to reduce contralateral rotational behaviour induced by 6-OHDA, directly correlates with its ability to revert PD motor impairment. 14,27 After 6-OHDA lesion in rats, forepaw adjusting step deficits is suggested as a model for akinesia of PD. Animals with a partial intra striatal lesion (50-70%) display deficits in the adjusted stepping test, which are maximal around two weeks postlesion.…”

Section: Discussionmentioning

confidence: 99%

“…All behavioral tests were performed on 1 st , 2 nd , 3 rd and 4 th week after the stereotactic injection of 6 OHDA in the striatum of rats. 14,15 To assess extent of neuronal loss. Rats were injected with apomorphine hydrochloride 0.5mg/kg IP.…”

Section: Neuro-behavioral Assessment 13mentioning

confidence: 99%

Evaluation of the protective effect of Paeonia emodi Wall on rat model of Parkinson’s disease induced by 6 hydroxy dopamine

Jalgaonkar

Kamble

Parmar

et al. 2018

Int J Basic Clin Pharmacol

View full text Add to dashboard Cite

Background: Generation of reactive oxygen species together with paucity of antioxidant defense is considered as an important cause for dopaminergic neuronal death. Review of literature indicates that none of the drugs so far studied for preventing the PD were found to be promising for use. Therefore, the present study was planned to evaluate the neuroprotective effect of Paeonia emodi Wall (PEW) in 6-hydroxy dopamine induced Parkinson’s disease (PD) model.Methods: The study was conducted on Wistar rats where Parkinson’s disease was induced by producing the striatal 6-hydroxy dopamine lesions. The test animals received ethanolic extract of PEW at dose of 200 and 300mg/kg for 28 days. Circling behavior, spontaneous locomotor activity, muscular coordination and akinesia were studied. Antioxidant levels were assessed by biochemical estimation and histopathology was carried out for dopaminergic neuronal loss.Results: PEW ethanolic extract showed significant dose dependent recovery in number of circlings, line crossing, muscular coordination and akinesia. A significant increase in MDA levels and decreased GSH level in PEW treated groups was observed in test groups as compared to control group (p<0.05). Normal architecture was retained only in PEW 300mg/Kg (p<0.05). L-Dopa did not showed effect on biochemical and histological parameters.Conclusions: The ethanolic extract of PEW showed neuroprotective activity against 6-hydroxy dopamine induced Parkinson’s disease in rats in both 200 and 300mg/kg doses. The protective action of PEW in PD can be because of its ability to reduce the oxidative stress.

show abstract

Place conditioning to apomorphine in rat models of Parkinson's disease: Differences by dose and side-effect expression

Cited by 14 publications

References 22 publications

Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson’s Disease: a Network Meta-Analysis

Comparison of the Efficacy of Different Drugs on Non-Motor Symptoms of Parkinson’s Disease: a Network Meta-Analysis

Dopamine and addiction: what have we learned from 40 years of research

Evaluation of the protective effect of Paeonia emodi Wall on rat model of Parkinson’s disease induced by 6 hydroxy dopamine

Contact Info

Product

Resources

About